FibroGen Inc (NASDAQ:FGEN) — Market Cap & Net Worth
Market Cap & Net Worth: FibroGen Inc (FGEN)
FibroGen Inc (NASDAQ:FGEN) has a market capitalization of $37.30 Million ($37.30 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #23079 globally and #5048 in its home market, demonstrating a 5.98% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying FibroGen Inc's stock price $9.22 by its total outstanding shares 4045445 (4.05 Million). Also see FibroGen Inc assets under control for a full breakdown of the balance sheet.
FibroGen Inc Market Cap History: 2015 to 2026
FibroGen Inc's market capitalization history from 2015 to 2026. Data shows change from $123.26 Million to $37.30 Million (-9.45% CAGR). Also see cash flow conversion of FibroGen Inc for how efficiently the company converts equity into cash flow.
Index Memberships
FibroGen Inc is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.67 Trillion | 0.00% | #656 of 976 |
|
NASDAQ Composite
IXIC
|
$41.95 Trillion | 0.00% | #2177 of 3165 |
Weight: FibroGen Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
FibroGen Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how FibroGen Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check FibroGen Inc stock quote for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
0.07x
FibroGen Inc's market cap is 0.07 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $123.26 Million | $180.83 Million | -$85.78 Million | 0.68x | N/A |
| 2016 | $86.57 Million | $179.58 Million | -$61.68 Million | 0.48x | N/A |
| 2017 | $191.75 Million | $125.67 Million | -$126.20 Million | 1.53x | N/A |
| 2018 | $187.22 Million | $212.96 Million | -$86.42 Million | 0.88x | N/A |
| 2019 | $173.51 Million | $256.58 Million | -$76.97 Million | 0.68x | N/A |
| 2020 | $150.05 Million | $176.32 Million | -$189.29 Million | 0.85x | N/A |
| 2021 | $57.04 Million | $235.31 Million | -$291.03 Million | 0.24x | N/A |
| 2022 | $64.81 Million | $140.73 Million | -$293.65 Million | 0.46x | N/A |
| 2023 | $3.59 Million | $46.80 Million | -$284.23 Million | 0.08x | N/A |
| 2024 | $2.14 Million | $29.62 Million | -$47.58 Million | 0.07x | N/A |
Competitor Companies of FGEN by Market Capitalization
Companies near FibroGen Inc in the global market cap rankings as of September 18, 2026. Review FibroGen Inc (FGEN) tangible net worth to assess the quality of the company's equity after excluding intangible assets.
Key companies related to FibroGen Inc by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #185 globally with a market cap of $130.87 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #337 globally with a market cap of $79.84 Billion USD.
- CSL Ltd (AU:CSL): Ranked #455 globally with a market cap of $60.95 Billion USD ( AU$86.14 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #504 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #185 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.87 Billion | $516.34 |
| #337 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $79.84 Billion | $789.45 |
| #455 | CSL Ltd | AU:CSL | $60.95 Billion | AU$177.56 |
| #504 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $158.07 |
FibroGen Inc Historical Marketcap From 2015 to 2026
Between 2015 and today, FibroGen Inc's market cap moved from $123.26 Million to $ 37.30 Million, with a yearly change of -9.45%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $37.30 Million | +5.01% |
| 2025 | $35.52 Million | +1558.17% |
| 2024 | $2.14 Million | -40.26% |
| 2023 | $3.59 Million | -94.47% |
| 2022 | $64.81 Million | +13.62% |
| 2021 | $57.04 Million | -61.98% |
| 2020 | $150.05 Million | -13.52% |
| 2019 | $173.51 Million | -7.32% |
| 2018 | $187.22 Million | -2.36% |
| 2017 | $191.75 Million | +121.50% |
| 2016 | $86.57 Million | -29.77% |
| 2015 | $123.26 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 18th, 2026 the market cap of FibroGen Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $37.30 Million USD |
| MoneyControl | $37.30 Million USD |
| MarketWatch | $37.30 Million USD |
| marketcap.company | $37.30 Million USD |
| Reuters | $37.30 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About FibroGen Inc
FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and o… Read more